Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesHematology/OncologyHighmark Pennsylvania sipuleucel‑T Coverage Update…
    Ask Trek AI about this page
    CurrentHighmark PennsylvaniaPolicy N/A

    Sipuleucel‑T (Provenge) for Metastatic Castrate‑Resistant Prostate Cancer

    Customize your policy alerts

    Sign up for all Highmark Pennsylvania policy alerts

    Know when Highmark Pennsylvania releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Highmark Pennsylvania coverage criteria for sipuleucel‑T (Provenge) for adults with metastatic castrate‑resistant prostate cancer and operational payment/applicability rules for providers and claims.

    Policy Summary
    PayerHighmark Pennsylvania
    PolicySipuleucel‑T (Provenge) for Metastatic Castrate‑Resistant Prostate Cancer
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateSep 26, 2016
    Last ReviewJun 20, 2016
    Next Review DateN/A
    Key ActionApply coverage criteria pre-payment for diagnosis codes and ensure documentation supports ECOG, PSA, testosterone, absence of visceral metastases, and life expectancy.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ECOG 0-1required performance status
    >=5.0PSA threshold
    <50 ng/dL

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    testosterone
    >6 molife expectancy
    Outpatientplace of service

    Coverage Criteria for Sipuleucel-T (Provenge)

    Medically Necessary Criteria

    Covered when ALL of the following are met:

    Eligibility for sipuleucel-T: Adult with metastatic castrate-resistant prostate cancer (mCRPC) who are asymptomatic or minimally symptomatic
    Castration status: Serum testosterone < 50 ng/dL< 50 ng/dL
    PSA level: Serum prostate specific antigen (PSA) >= 5.0 ng/mL>= 5.0 ng/mL
    Performance status: Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1ECOG 0 or 1
    Metastatic pattern: No visceral metastases (no liver, lung, or brain metastases)
    Pain management: No use of narcotics for cancer-related pain
    Life expectancy greater than 6 months> 6 months
    Definition of mCRPC: Disease progression evidenced by a progressively rising PSA (defined as a PSA rise by 2 ng/mL or more above the nadir) or an increase in tumor mass on imaging (bone scan, X-ray, CT, or MRI) despite castrate testosterone < 50 ng/dL.

    mCRPC defined as above

    Use of sipuleucel-T for any indication not listed in this policy is considered experimental/investigational and non‑covered.

    Any use of sipuleucel‑T outside the specified indications and criteria in this policy (including indications not listed) is non‑covered as experimental/investigational.

    Covered Regimens and Indications

    RegimenIndication / EligibilityCoverage Status
    Sipuleucel-T (Provenge)Asymptomatic or minimally symptomatic adults with metastatic castrate-resistant prostate cancer (mCRPC) who meet ALL of the following: serum testosterone < 50 ng/dL; PSA >= 5.0 ng/mL; ECOG performance status 0 or 1; no visceral (liver, lung, or brain) metastases; no use of narcotics for cancer-related pain; life expectancy > 6 months. mCRPC is defined as disease progression with a PSA rise of >= 2 ng/mL above nadir or increased tumor mass on imaging despite castrate testosterone <50 ng/dL.Covered

    Coding and Clinical Thresholds

    Diagnosis codes (applied pre-payment)ICD-10
    No codes listed
    inv-05: PSA — >= 5.0 ng/mL
    PSA threshold>= 5.0 ng/mL
    ContextRequired as part of eligibility for sipuleucel-T in mCRPC; listed with other clinical criteria
    Measurement unitsng/mL
    inv-06: Testosterone — < 50 ng/dL
    Testosterone threshold< 50 ng/dL
    ContextMust be castrate level to qualify for sipuleucel-T (part of mCRPC criteria)
    Measurement unitsng/dL

    Provider Actions, Billing, and Review

    Prior Authorization

    Pre-payment diagnosis codes; post-payment retrospective review

    Coverage determination and diagnosis codes are applied on a pre-payment basis. Professional and facility services are processed initially (post-payment) and are subject to retrospective review; diagnosis codes remain a pre-payment application within the policy.

    • Diagnosis codes are applied on a pre-payment basis.
    • Professional claims: policy applied on a post-payment basis — services pay on initial processing and are subject to retrospective review.
    • Facility claims: policy applied on a post-payment basis — services pay on initial processing and are subject to retrospective review.
    Step Therapy

    No step therapy requirement

    No step therapy or prerequisite trials are specified in this policy; eligibility is determined solely by the clinical coverage criteria listed (e.g., mCRPC status, PSA, testosterone, ECOG, absence of visceral metastases, life expectancy, and narcotic use).

    Definitions

    inv-14: metastatic castrate-resistant prostate cancer defined as disease progression with rising PSA (PSA rise by 2 ng/mL or more above nadir) or increase in tumor mass on imaging despite castrate testosterone <50 ng/dL
    DefinitionmCRPC: disease progression evidenced by a progressively rising PSA (PSA rise by 2 ng/mL or more above the nadir) or an increase in tumor mass on bone scan, X‑ray, CT or MRI despite a castrate level of testosterone <50 ng/dL.
    Alternate phrasingMetastatic castrate‑resistant prostate cancer is androgen‑independent metastatic disease demonstrating biochemical (PSA) or radiographic progression despite castrate testosterone.
    Relevant testsSerial PSA measurements and imaging (bone scan, X‑ray, CT, MRI) to document progression

    Background

    Sipuleucel‑T is an autologous cellular immunotherapy composed of patient‑derived antigen‑presenting cells exposed ex vivo to prostate antigen–containing fusion proteins intended to stimulate the patient’s immune system to resist spread of metastatic castrate‑resistant prostate cancer. It is indicated for asymptomatic or minimally symptomatic adult patients with mCRPC who meet the physiologic and disease‑specific criteria listed in this policy (including serum testosterone < 50 ng/dL, PSA ≥ 5.0 ng/mL, ECOG 0–1, absence of visceral metastases, no narcotic use for cancer‑related pain, and life expectancy > 6 months).

    Policy Summary
    PayerHighmark Pennsylvania
    PolicySipuleucel‑T (Provenge) for Metastatic Castrate‑Resistant Prostate Cancer
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateSep 26, 2016
    Last ReviewJun 20, 2016
    Next Review DateN/A
    Key ActionApply coverage criteria pre-payment for diagnosis codes and ensure documentation supports ECOG, PSA, testosterone, absence of visceral metastases, and life expectancy.
    SourceLink
    On This Page
    Coverage Criteria for Sipuleucel-T (Provenge)Covered Regimens and IndicationsCoding and Clinical ThresholdsProvider Actions, Billing, and ReviewDefinitionsBackground
    inv-07: Life expectancy — > 6 months
    Life expectancy requirement> 6 months
    ContextRequired for eligibility for sipuleucel-T in mCRPC; stated among coverage criteria
    ApplicationAssessed by treating clinician; documented in medical record
    inv-08: ECOG performance status — 0 or 1
    ECOG performance status requirement0 or 1
    ContextMust be ECOG 0–1 to be eligible for sipuleucel-T (see Table Attachment)
    AssessmentDocumented in medical record prior to treatment
    • Eligibility must meet the clinical criteria in the COVERAGE CRITERIA section (PSA ≥ 5.0 ng/mL, testosterone <50 ng/dL, ECOG 0–1, etc.).
    Documentation Required

    Signed advance notice and member agreement for E/I services; document eligibility

    If a provider intends to bill the member for a service deemed experimental/investigational, they must give advance written notice, obtain a signed cost‑agreement from the member, and retain that signed agreement in the provider’s records; medical records should support eligibility criteria (ECOG, PSA, testosterone, absence of visceral metastases, life expectancy, narcotic use).

    • Provide advance written notice to the member that the service is deemed experimental/investigational and include an estimate of cost.
    • Obtain the member’s written agreement to assume financial responsibility before delivering the service and maintain the signed agreement in the medical record.
    • Document clinical eligibility criteria in the medical record (ECOG, PSA, testosterone, absence of visceral metastases, life expectancy, narcotic use).
    Denial Risk

    Denial risk for non-concordant indications; member billing permitted with advance agreement

    Services that do not meet the policy’s coverage criteria will be considered experimental/investigational and may be denied; network providers may bill the member only after providing advance written notice and obtaining the member’s signed cost agreement.

    • Any use outside the specified indications and criteria is non-covered as experimental/investigational.
    • If service is E/I, obtain advance written notice with cost estimate and signed member agreement prior to providing the service.